Founded in 2018, Shanghai-based Ruining Bio has built a proprietary medical hydrogel technology platform aimed at supplying breakthrough devices for major clinical scenarios, particularly in oncology. Its pipeline includes China-first and potential global best-in-class products such as an absorbable spacer hydrogel for tumor radiotherapy and a tumor-embolizing hydrogel for interventional oncology; both products have been accepted into the National Medical Products Administration’s innovative device fast-track (green channel) program. The company is also advancing hydrogels for indications like intrauterine adhesion prevention, creating a multi-segment product matrix. Ruining Bio’s founder and CEO, Dr. Pan Zhen, holds a Ph.D. in polymer science from Fudan University and has been recognized on multiple national talent and entrepreneurship lists. Proceeds from recent financing will be used to accelerate clinical trials and commercialization efforts globally. No revenue or user metrics were disclosed in the articles.

Total raised

$30M

Funding rounds

3

Latest round

Series B

Latest activity

Jan 2024